EVIDENT=Evaluating V-Go Insulin Delivery in Type 2 Diabetes.
*P<0.0001 compared to baseline.
N=88 at 15 weeks with baseline A1c of 9.6% and n=71 at 34 weeks with baseline A1c of 9.6%. V-Go insulin dosing included supplemental insulin in 5 patients (the EVIDENT study).
Compared to previous MDI treatment, V-Go provided additional A1c reductions that were maintained through 26 weeks2,†‡
†Reduction in A1c (P<0.0001) compared to baseline.2
‡Prior to V-Go initiation, patients had a mean A1c of 9.4%.2
Based on a real-world, retrospective database analysis of an electronic medical record database. Patients were adults diagnosed with diabetes mellitus, A1c ≥7%, and previously prescribed basal-bolus insulin therapy. A total of 86 patients were evaluated (the VALIDATE study).
TDD=total daily dose.
A retrospective analysis of electronic medical records to identify patients switched from an insulin pen device or syringe to insulin delivery with V-Go (n=88).
*Patients were prescribed basal-bolus or premix at baseline.
†P<0.001 compared to baseline; ‡P=0.007 compared to baseline (the EVIDENT study).
V-Go insulin dosing included supplemental insulin in 5 patients.1
Compared to previous MDI treatment, V-Go significantly reduced TDD of insulin by 40% to 48%2,3
MDI=multiple daily injections; TDD=total daily dose.
*Reduction in TDD (P<0.0001) compared to baseline.2
†Lower limit represents the primary dose excluding titration and correction, and the upper limit allowed additional units to optimize insulin therapy (titration, correction, sliding scale) as prescribed (the VALIDATE study).
‡Patients reported taking a mean TDD of 88 U/day of insulin prior to V-Go initiation.2
References: 1. Harrison HC, Everitt B, Nikkel C. Poster: The Impact of utilizing a novel insulin delivery device in patients with type 2 diabetes. Presented at ACCE. May 2017. 2. Lajara R, Nikkel C. Poster: Evaluating the effect of V-Go therapy in sub-optimally controlled patients with diabetes: a retrospective cohort analysis on a large specialized diabetes system. Presented at ACCE. May 2015. 3. Data on File. Zealand Pharma A/S. August 16, 2016.